S&P 5007,489.72▲0.7% Nasdaq25,373.85▲1.0% Dow52,485.03▲0.5% Russell 2K2,931.34▼0.5% 10-Yr4.75%+8bp VIX15.99−1.10 WTI$86.80▲3.8% Gold$4,098.60▼0.0% EUR/USD1.153▲0.5% BTC$63,780▲0.5% Nikkei61,867▲0.7%
At close · Fri, Jul 31, 2026
Daily Market Updates.

US Markets

Home›US Markets›M&A & Deals›AstraZeneca and Bristol Myers Squibb in reported merge…

AstraZeneca and Bristol Myers Squibb in reported merger talks

Reported · Written up by our desk · M&A & Deals

MarketWatch reported that AstraZeneca and Bristol Myers Squibb are in discussions about a potential merger, a development that has drawn sharp investor attention.

According to MarketWatch, AstraZeneca shares were falling while Bristol Myers Squibb shares were rising on Monday as the market reacted to the reported talks.

The outlet said analysts are focusing on what would drive the companies to pursue a combination, given the apparent mismatch in near term stock moves between the two firms.

← Newer storyMiller completes acquisition of Dubai reinsurance broker Shields

More like this

US MarketsConexeu Sciences targets FDA 510(k) filing for bioresorbable scaffold
US MarketsJPMorgan to invest $750 billion to expand US housing supply
US MarketsAstraZeneca shares fall on reported Bristol Myers merger talks
US MarketsAstraZeneca and Bristol-Myers Squibb tie-up talks roil shares
US MarketsAstraZeneca in talks to buy Bristol Myers Squibb in near-$400bn deal

Sources

MarketWatchAn AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it ‘odd’
MarketWatchAn AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it ‘odd’

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.